Juraj Adamik, PhD
About Juraj Adamik, PhD
Juraj Adamik, PhD, is a Scientist II at RAPT Therapeutics, specializing in immune regulation and cancer vaccines. He has extensive experience in research roles at prestigious institutions, focusing on tumor-suppressive mechanisms and enhancing therapeutic efficacy for melanoma patients.
Work at Rapt Therapeutics
Juraj Adamik, PhD, has been employed as a Scientist II at RAPT Therapeutics since 2022. In this role, he utilizes high-dimensional and single cell-based approaches to identify tumor-suppressive mechanisms and immune tolerance. His work focuses on discovering actionable targets and biomarkers that can enhance the therapeutic efficacy of cancer vaccines.
Previous Research Experience
Prior to his current position, Juraj Adamik worked at the University of Pittsburgh School of Medicine as a Research Associate from 2016 to 2019. He also held a Research Associate position at the University of California, San Francisco from 2019 to 2022. Additionally, he was a Postdoctoral Researcher at the University of Pittsburgh School of Medicine from 2013 to 2016 and worked as a Research Scientist at the Parker Institute for Cancer Immunotherapy during the same period as his role at UCSF.
Education and Expertise
Juraj Adamik earned his Doctor of Philosophy (PhD) in Cell/Cellular and Molecular Biology from Duquesne University, where he studied from 2007 to 2012. He furthered his education at the University of California, San Francisco. His academic background supports his specialization in immune regulation of dendritic cell cancer vaccines, particularly for melanoma patients.
Research Focus and Goals
Juraj Adamik aims to integrate his postdoctoral training in molecular biology and in vivo mouse models with human translational immune-oncology research. His research is centered on identifying tumor-suppressive mechanisms and enhancing the efficacy of cancer vaccines through the study of immune regulation.